and personalized healthcare
REAL-WORLD DATA (RWD) AND EVIDENCE (RWE)
The 21st Century Cures Act, passed in 2016, places additional focus on the use of these types of data to support regulatory decision making, including approval of new indications for approved drugs (US FDA).
Real-world data (RWD) are the data relating to patient health and the delivery of healthcare collected from a variety of sources including EHR, claims and billing activities, registries, patient data and mobile devices.
Real-world evidence (RWE) is the clinical evidence regarding the use and potential benefits or risks of a medical product derived from analysis of RWD via observational studies, pragmatic trials or other methods.
Syreon combines many streams of RWD including patient health data and resource utilization to monitor postmarket safety and adverse events, and to develop decision support tools for clinical practice.
PERSONALIZED HEALTHCARE STRATEGIES
Informed, connected and affluent populations demand access to, and delivery of, new treatments closer to home for convenience and efficiency via outreach programs with expert systems and telemedicine support.
Major providers such as Kaiser Permanente now conduct more consultations virtually than in person (52% of 111 million), with improved patient satisfaction. This will become the norm within a decade!
But developing precise and efficient care strategies for personalized health is challenging and a critical component of the treatment process. This is where Syreon excels!